Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
didodecyl-methotrexate
- Development stage
- Preclinical
- Lead developer
- InCor
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Didodecyl-methotrexate (ddMTX) is a lipophilic derivative of methotrexate, chemically produced by esterification of methotrexate with dodecyl groups. Designed to enhance drug delivery and cellular uptake, ddMTX is typically formulated with lipid nanoemulsions (LDE-ddMTX) for improved pharmacokinetics and cytotoxicity. Preclinical studies demonstrate that ddMTX has markedly higher cytotoxicity compared to methotrexate when used in nanoparticle formulations, with potential therapeutic applications in cancer and diseases where methotrexate is already used. Increased lipophilicity is intended to optimize passive transport and intracellular concentration, though the clinical use remains investigational.[2]
- Other names
- ddMTXdidodecyl methotrexate
02
Targets
DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on didodecyl-methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on didodecyl-methotrexate.